Cryogenic OGS Ltd reports H1 FY27 PAT of ₹7.37 crore

Cryogenic OGS Ltd reported consolidated profit after tax of ₹7.37 crore for the half-year ended September 30, 2026. The company’s board approved the unaudited H1 FY27 results on October 29, while the disclosed summary indicated 85% revenue growth, 124% EBITDA growth and 361% PAT growth for the period.

What did Cryogenic OGS Ltd announce for H1 FY27?

Cryogenic OGS Ltd announced that its board approved unaudited standalone and consolidated financial results for the half-year ended September 30, 2026. The approval was given at the board meeting held on October 29, 2026, and marks the company’s first official disclosure of its H1 FY27 financial figures to investors.

The results disclosure includes the financial statements, limited review reports and a statement of deviation. These documents were prepared under the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015, and applicable Indian Accounting Standards. The company also reported consolidated profit after tax of ₹7.37 crore for H1 FY27.

How did Cryogenic OGS perform during the half-year?

Cryogenic OGS reported growth of 85% in revenue, 124% in EBITDA and 361% in profit after tax for H1 FY27, according to the results summary provided with the announcement. Separately, the disclosure stated that standalone revenue increased 44% year on year and that margins improved during the period.

The source material does not provide the comparable absolute revenue, EBITDA or profit figures for H1 FY26, nor does it provide an absolute H1 FY27 revenue figure. As a result, the reported growth rates show the direction of performance, while a full assessment of the financial base and segment-level contribution requires the detailed financial statements accompanying the filing.

What does the limited review report mean for investors?

The limited review report provides moderate assurance on the unaudited financial information but does not represent an audit opinion. This is the standard distinction for interim financial reporting, where the reviewer performs procedures that are narrower in scope than a full audit.

For investors, the board approval and limited review make the H1 FY27 figures a formal regulatory disclosure rather than preliminary management commentary. However, the results remain unaudited. The accompanying statement of deviation is also relevant because it is part of the company’s compliance disclosure under SEBI regulations.

What business does Cryogenic OGS serve?

Cryogenic OGS operates in precision fluid-handling equipment used by India’s oil, gas and emerging clean-fuel networks. Its stated product areas include metering skids, filters and dosing systems used at refineries, pipelines and fuel terminals to measure, clean and blend fuel flows.

This operating context is important because demand for such equipment is linked to project activity and operating requirements across energy infrastructure. The company has also indicated visibility for good orders of similar size in the first half of FY27 and through the financial year, although the supplied information does not quantify the order book or specify individual contracts.

How does the H1 FY27 update compare with earlier disclosures?

The H1 FY27 disclosure follows Cryogenic OGS’s FY26 annual-report submission in July 2026 and its virtual annual general meeting scheduled for August 20, 2026. It also follows the company’s prior investor communications on financial performance and operations.

For H2 FY26, the company had reported revenue of ₹19.76 crore, EBITDA of ₹6.63 crore and profit after tax of ₹4.67 crore. H2 FY26 EBITDA margin was reported at 33.56%, while PAT margin was 23.62%. Those earlier figures provide historical context, but they should not be treated as directly comparable with the H1 FY27 growth percentages without reviewing the complete half-year financial statements.

The H1 FY27 announcement provides investors with a reported improvement in revenue, operating profit and net profit growth. No share-price movement, valuation impact or analyst response was included in the supplied filing information. The immediate market relevance is therefore the formal availability of the half-year numbers and supporting review documentation.

Conclusion

Cryogenic OGS Ltd’s H1 FY27 results indicate reported growth across revenue, EBITDA and profit after tax, with consolidated PAT of ₹7.37 crore. The board-approved filing also provides standalone and consolidated statements under the SEBI disclosure framework, supported by a limited review rather than a full audit opinion.

Investors will next watch for the detailed financial statements, any further disclosures on order execution and the company’s progress against its stated expectation of good order inflows through FY27. The available information does not quantify the order pipeline, making subsequent regulatory filings important for assessing operational visibility.